Verastem (VSTM) Quick Ratio: History & Chart

Verastem, Inc.(VSTM)

Biotechnology · Needham, MA

$7.75-0.25 (-3.13%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Verastem, Inc.

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

Needham, MA

102 employees

www.verastem.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel W. Paterson

View full financials

VSTM Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

2.22

QUICK RATIO (ACID-TEST) AVG TTM

2.86

QUICK RATIO (ACID-TEST) AVG 3Y

3.38

QUICK RATIO (ACID-TEST) AVG 5Y

4.88

QUICK RATIO (ACID-TEST) AVG 10Y

5.33

QUICK RATIO (ACID-TEST) AVG 15Y

8.29

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

-22.12%

CURRENT VS 3Y AVG

-34.25%

CURRENT VS 5Y AVG

-54.47%

CURRENT VS 10Y AVG

-58.24%

CURRENT VS 15Y AVG

-73.16%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

3.35

median of 870 covered companies

CURRENT VS SECTOR MEDIAN

-33.71%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Verastem, Inc. (VSTM)	$681.02M	2.22	2.86	3.38	4.88
Solid Biosciences Inc. (SLDB)vs ›	$681.27M	13.82	5.67	7.51	7.66
Anteris Technologies Global Corp. (AVR)vs ›	$685.49M	14.20	2.59	2.42	2.06
MiMedx Group, Inc. (MDXG)vs ›	$673.41M	4.79	3.80	3.38	3.21
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$691.79M	8.86	10.22	11.35	25.38
Faeth Therapeutics, Inc. (FTH)vs ›	$693.19M	19.69	6.38	9.16	11.87
Wave Life Sciences Ltd. (WVE)vs ›	$693.61M	9.99	4.68	3.00	2.74
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	3.86	4.81	5.95	7.14
Helus Pharma Inc. (HELP)vs ›	$666.95M	10.97	8.63	10.75	10.66
Annexon, Inc. (ANNX)vs ›	$660.29M	5.53	8.02	10.47	14.43

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Verastem, Inc. (VSTM)

$681.02M

2.22

2.86

3.38

4.88

Solid Biosciences Inc. (SLDB)vs ›

$681.27M

13.82

5.67

7.51

7.66

Anteris Technologies Global Corp. (AVR)vs ›

$685.49M

14.20

2.59

2.42

2.06

MiMedx Group, Inc. (MDXG)vs ›

$673.41M

4.79

3.80

3.38

3.21

Olema Pharmaceuticals, Inc. (OLMA)vs ›

$691.79M

8.86

10.22

11.35

25.38

Faeth Therapeutics, Inc. (FTH)vs ›

$693.19M

19.69

6.38

9.16

11.87

Wave Life Sciences Ltd. (WVE)vs ›

$693.61M

9.99

4.68

3.00

2.74

Cytek Biosciences, Inc. (CTKB)vs ›

$694.79M

3.86

4.81

5.95

7.14

Helus Pharma Inc. (HELP)vs ›

$666.95M

10.97

8.63

10.75

10.66

Annexon, Inc. (ANNX)vs ›

$660.29M

5.53

8.02

10.47

14.43

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Verastem, Inc. (VSTM)?

The quick ratio (acid-test) for VSTM stock is 2.22.

Is Verastem, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 2.22 is 54% below its 5-year average of 4.88, near the low end of its 5-year range (2.22–9.14).

What is the TTM average quick ratio (acid-test) for Verastem, Inc. (VSTM)?

The TTM average quick ratio (acid-test) for VSTM stock is 2.86.

What is the 3Y average quick ratio (acid-test) for Verastem, Inc. (VSTM)?

The 3Y average quick ratio (acid-test) for VSTM stock is 3.38.

What is the 5Y average quick ratio (acid-test) for Verastem, Inc. (VSTM)?

The 5Y average quick ratio (acid-test) for VSTM stock is 4.88.

What is the 10Y average quick ratio (acid-test) for Verastem, Inc. (VSTM)?

The 10Y average quick ratio (acid-test) for VSTM stock is 5.33.

What is the 15Y average quick ratio (acid-test) for Verastem, Inc. (VSTM)?

The 15Y average quick ratio (acid-test) for VSTM stock is 8.29.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	2.22
2026-03-31	3.00
2025-12-31	3.07
2025-09-30	2.55
2025-06-30	3.44
2025-03-31	3.50
2024-12-31	3.07
2024-09-30	3.23
2024-06-30	3.28
2024-03-31	4.40
2023-12-31	5.45
2023-09-30	7.33
2023-06-30	9.14
2023-03-31	5.32
2022-12-31	4.29
2022-09-30	4.97
2022-06-30	4.87
2022-03-31	6.72
2021-12-31	5.69
2021-09-30	8.03
2021-06-30	9.01
2021-03-31	10.78
2020-12-31	8.48
2020-09-30	5.00
2020-06-30	4.80
2020-03-31	5.61
2019-12-31	2.74
2019-09-30	5.46
2019-06-30	6.15
2019-03-31	7.56
2018-12-31	6.82
2018-09-30	2.97
2018-06-30	7.70
2018-03-31	4.45
2017-12-31	5.13
2017-09-30	3.12
2017-06-30	5.40
2017-03-31	5.59
2016-12-31	7.40
2016-09-30	14.04
2016-06-30	15.79
2016-03-31	16.42
2015-12-31	10.96
2015-09-30	11.15
2015-06-30	13.49
2015-03-31	14.26
2014-12-31	10.36
2014-09-30	11.27
2014-06-30	12.65
2014-03-31	16.67
2013-12-31	13.06
2013-09-30	17.70
2013-06-30	11.13
2013-03-31	20.13
2012-12-31	23.79
2012-09-30	15.01
2012-06-30	12.20
2012-03-31	14.15
2011-12-31	15.24
2011-09-30	30.79
2011-06-30	0.00
2011-03-31	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

2.22

2026-03-31

3.00

2025-12-31

3.07

2025-09-30

2.55

2025-06-30

3.44

2025-03-31

3.50

2024-12-31

3.07

2024-09-30

3.23

2024-06-30

3.28

2024-03-31

4.40

2023-12-31

5.45

2023-09-30

7.33

2023-06-30

9.14

2023-03-31

5.32

2022-12-31

4.29

2022-09-30

4.97

2022-06-30

4.87

2022-03-31

6.72

2021-12-31

5.69

2021-09-30

8.03

2021-06-30

9.01

2021-03-31

10.78

2020-12-31

8.48

2020-09-30

5.00

2020-06-30

4.80

2020-03-31

5.61

2019-12-31

2.74

2019-09-30

5.46

2019-06-30

6.15

2019-03-31

7.56

2018-12-31

6.82

2018-09-30

2.97

2018-06-30

7.70

2018-03-31

4.45

2017-12-31

5.13

2017-09-30

3.12

2017-06-30

5.40

2017-03-31

5.59

2016-12-31

7.40

2016-09-30

14.04

2016-06-30

15.79

2016-03-31

16.42

2015-12-31

10.96

2015-09-30

11.15

2015-06-30

13.49

2015-03-31

14.26

2014-12-31

10.36

2014-09-30

11.27

2014-06-30

12.65

2014-03-31

16.67

2013-12-31

13.06

2013-09-30

17.70

2013-06-30

11.13

2013-03-31

20.13

2012-12-31

23.79

2012-09-30

15.01

2012-06-30

12.20

2012-03-31

14.15

2011-12-31

15.24

2011-09-30

30.79

2011-06-30

0.00

2011-03-31

0.00

Quick Ratio (Acid-Test): 2.22

VSTM Quick Ratio

VSTM Average Quick Ratio (Acid-Test) Chart

VSTM Current vs Average Quick Ratio (Acid-Test) Chart

VSTM Quick Ratio (Acid-Test) Metrics

VSTM Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

VSTM Quick Ratio (Acid-Test) History

Related Metrics